Atopic Dermatitis Eczema

Immunology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AnaptysBio
AnaptysBioSAN DIEGO, CA
1 program
1
ANB032Phase 21 trial
Active Trials
NCT05935085TerminatedEst. Jan 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
AnaptysBioANB032

Clinical Trials (1)

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

Start: Jun 2023Est. completion: Jan 2025
Phase 2Terminated

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space